Trobix Bio

Trobix Bio Overview

Trobix Bio is an Israeli biotech company pioneering the field of human microbiome via its TBX™ technology platform, utilizing CRISPR, phage and synthetic biology to re-program specific activities in targeted microbiome bacteria and develop orally administered precision oncology therapeutics. Targeting cumulative markets of over $4 billion, Trobix’s preclinical products, TBX201 and TBX301, are being developed to reduce severe diarrhea and colitis in patients receiving irinotecan or checkpoint inhibitors, respectively. Its products may allow physicians to complete more oncology treatments and improve cancer patients’ quality of life. Trobix Bio is a spin-off company of Ramot, the technology-transfer company of Tel Aviv University.

Cumulative Funding Raised Over Time ($)

Latest News

Mar 30, 2023 · www.globenewswire.com

growth-positive

Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics

Trobix Bio has successfully closed a $3 million equity investment by Chartered Group. The investment will be used to advance the development of Trobix Bios precision microbiome oncology therapeutics, which aim to address the gastrointestinal side effects of oncology treatments and other gastrointestinal diseases impacted by the microbiome. Trobix Bios CEO expressed gratitude for the investment and highlighted the significant unmet need for treatments that relieve side effects caused by cancer therapeutics. Chartered Groups Chairman praised Trobix Bios technology and team, stating that they believe the company will deliver products that make a huge impact on human wellbeing. Trobix Bios proprietary TBX™ platform technology utilizes computational, synthetic, and synthetic biology technologies to engineer phages as medicines that reprogram targeted microbiome bacteria. The companys lead therapeutic candidates, TBX201 and TBX301, aim to reduce severe diarrhea caused by irinotecan and colitis in patients receiving immune checkpoint inhibitors, respectively.

Investment

Jul 29, 2020 · www.prnewswire.com

growth-positive

Trobix Bio completed Series A funding by a leading Japanese/Singapore fund

Trobix Bio, a biotechnology company, has announced the closing of a US $3 million Series A funding from its lead investor, Chartered Opus. The funding will be used to advance the companys antimicrobial resistance platform technology and the pre-clinical development of its lead product, TBX101. Trobix Bio aims to develop phage-based products that sensitize bacterial pathogens to antibiotics and treat patients carrying gut antimicrobial resistant bacteria. The funding is seen as a positive growth opportunity for the company. Chartered Opus, a production platform for investment products, is the preferred investment vehicle for the Chartered Group High-Tech division.

Investment

Jul 6, 2020 · ramot.org

Ramot- Technology Transfer Company of Tel Aviv University

Mar 6, 2019 · globaluniversityventuring.com

growth-positive

Trobix Bio follows the funding trail - Global Venturing

Trobix Bio, an Israel-based developer of enhanced antibiotics spun out of Tel Aviv University research, has received undisclosed funding led by Chartered Opus.

Investment

Funding

Team Members

2

Employees: 1-10

Web & Social Links

Locations

HaMelacha St 45, Netanya, Israel

Photos & Videos

1 item(s)

Trobix Bio Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info